Kingswood Wealth Advisors LLC Purchases 172,913 Shares of Pfizer Inc. (NYSE:PFE)

Kingswood Wealth Advisors LLC raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 271.2% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 236,683 shares of the biopharmaceutical company's stock after acquiring an additional 172,913 shares during the quarter. Kingswood Wealth Advisors LLC's holdings in Pfizer were worth $5,842,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rialto Wealth Management LLC bought a new position in Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. bought a new position in Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new position in Pfizer in the fourth quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer in the fourth quarter valued at approximately $30,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 0.5%

Shares of NYSE:PFE traded down $0.13 during midday trading on Thursday, reaching $23.88. 37,055,113 shares of the company were exchanged, compared to its average volume of 41,246,625. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a fifty day simple moving average of $23.17 and a two-hundred day simple moving average of $24.92. The firm has a market cap of $135.74 billion, a PE ratio of 17.30, a P/E/G ratio of 0.87 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the business posted $0.82 earnings per share. The firm's quarterly revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.20%. Pfizer's payout ratio is 124.64%.

Analysts Set New Price Targets

A number of brokerages have issued reports on PFE. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. Finally, UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.